MAZEN A HANNA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
- Where
- INDEPENDENCE, OH
- NPI
- 1033128731
- Received
- $257,295 in 163 records, 2019 to 2025 ($207,845 general, $49,450 research)
- As principal investigator
- $1,404,162 of research payments to others in 88 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 37 | $46,995 |
| 2025 | Research payment | 12 | $12,570 |
| 2024 | General payment | 31 | $60,161 |
| 2024 | Research payment | 8 | $7,790 |
| 2023 | General payment | 22 | $35,815 |
| 2023 | Research payment | 7 | $11,370 |
| 2022 | General payment | 6 | $13,676 |
| 2022 | Research payment | 5 | $6,030 |
| 2021 | General payment | 2 | $3,600 |
| 2021 | Research payment | 2 | $1,270 |
| 2020 | General payment | 5 | $28,980 |
| 2020 | Research payment | 9 | $10,420 |
| 2019 | General payment | 17 | $18,617 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 73 | $146,936 | 2019–2025 |
| Alnylam Pharmaceuticals Inc. | 37 | $69,401 | 2019–2025 |
| Alexion Pharmaceuticals, Inc. | 11 | $18,179 | 2022–2025 |
| AstraZeneca Pharmaceuticals LP | 9 | $5,935 | 2022–2024 |
| AstraZeneca UK Limited | 4 | $4,602 | 2024–2025 |
| Novo Nordisk AS | 1 | $3,750 | 2022 |
| Akcea Therapeutics, Inc. | 1 | $3,175 | 2020 |
| Novo Nordisk Inc | 1 | $3,100 | 2024 |
| Abbott Laboratories | 6 | $439 | 2023–2025 |
| Impulse Dynamics (USA) Inc. | 3 | $331 | 2023–2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $213 | 2019–2023 |
| CVRx, Inc. | 1 | $168 | 2025 |
| Paragonix Technologies, Inc. | 3 | $160 | 2024 |
| ABIOMED | 2 | $148 | 2019–2025 |
| BridgeBio Pharma, Inc. | 1 | $143 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $124 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 1 | $124 | 2023 |
| scPharmaceuticals Inc. | 1 | $115 | 2025 |
| Lilly USA, LLC | 2 | $91 | 2019 |
| Life Molecular Imaging Ltd | 1 | $90 | 2022 |
| Kestra Medical Technology Services, Inc. | 1 | $62 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 33 | $114,145 |
| Research payment | 43 | $49,450 |
| Travel and Lodging | 24 | $40,369 |
| Honoraria | 6 | $33,065 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 8 | $16,092 |
| Food and Beverage | 49 | $4,173 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Abbott Laboratories | $90 | Food and Beverage | In-kind items and services | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart | 2025 | |
| 2025-12-11 | Alexion Pharmaceuticals, Inc. | $1,050 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-09 | PFIZER INC. | $5,200 | Consulting Fee | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-12-09 | PFIZER INC. | $2,600 | Consulting Fee | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-12-08 | PFIZER INC. | $1,820 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-12-02 | PFIZER INC. | $780 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-11-27 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-11-20 | AstraZeneca UK Limited | $650 | Consulting Fee | Cash or cash equivalent | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-11-19 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-10-15 | Alexion Pharmaceuticals, Inc. | $8,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-02 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-09-29 | Alexion Pharmaceuticals, Inc. | $610 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-28 | PFIZER INC. | $64 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-09-26 | Alexion Pharmaceuticals, Inc. | $968 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-23 | PFIZER INC. | $780 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-09-19 | Alnylam Pharmaceuticals Inc. | $1,319 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-09-19 | AstraZeneca UK Limited | $1,300 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-17 | PFIZER INC. | $39 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-09-05 | BridgeBio Pharma, Inc. | $143 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-08-30 | AstraZeneca UK Limited | $52 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-29 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-08-29 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-08-29 | Alexion Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-27 | Alnylam Pharmaceuticals Inc. | $448 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-27 | Alnylam Pharmaceuticals Inc. | $407 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-27 | Alnylam Pharmaceuticals Inc. | $407 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-19 | Alnylam Pharmaceuticals Inc. | $356 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-18 | Alnylam Pharmaceuticals Inc. | $11,665 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-13 | PFIZER INC. | $780 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-08-12 | Alnylam Pharmaceuticals Inc. | $902 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-12 | Alnylam Pharmaceuticals Inc. | $115 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-07-31 | Alnylam Pharmaceuticals Inc. | $149 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2025 | |
| 2025-06-25 | Alexion Pharmaceuticals, Inc. | $1,050 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-17 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-05-13 | ABIOMED | $126 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-17 | PFIZER INC. | $3,200 | Consulting Fee | Cash or cash equivalent | VYNDAMAX Drug, CARDIOVASCULAR | 2025 | |
| 2025-04-14 | CVRx, Inc. | $168 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-04-10 | Impulse Dynamics (USA) Inc. | $27 | Food and Beverage | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | 2025 | |
| 2025-04-02 | PFIZER INC. | $886 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-03-29 | PFIZER INC. | $508 | Travel and Lodging | In-kind items and services | VYNDAMAX Drug, CARDIOVASCULAR | 2025 | |
| 2025-03-29 | Alexion Pharmaceuticals, Inc. | $90 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-21 | Alexion Pharmaceuticals, Inc. | $700 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-20 | Alexion Pharmaceuticals, Inc. | $875 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-28 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-02-28 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-02-28 | scPharmaceuticals Inc. | $115 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-02-19 | PFIZER INC. | $1,400 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2025 |
| 2025-02-12 | Alnylam Pharmaceuticals Inc. | $148 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-16 | Alnylam Pharmaceuticals Inc. | $2,467 | Consulting Fee | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | 2025 | |
| 2024-12-31 | PFIZER INC. | $6,500 | Consulting Fee | Cash or cash equivalent | VYNDAMAX Drug, CARDIOVASCULAR | 2024 | |
| 2024-12-30 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | VYNDAQEL CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-12-19 | PFIZER INC. | $8,448 | Consulting Fee | Cash or cash equivalent | VYNDAMAX Drug, CARDIOVASCULAR | 2024 | |
| 2024-12-17 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | VYNDAQEL CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-12-09 | PFIZER INC. | $3,200 | Consulting Fee | Cash or cash equivalent | VYNDAMAX Drug, CARDIOVASCULAR | 2024 | |
| 2024-12-04 | Novo Nordisk Inc | $3,100 | Consulting Fee | Cash or cash equivalent | Biological | 2024 | |
| 2024-11-29 | PFIZER INC. | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENEFIX Biological, HEMATOLOGY | 2024 | |
| 2024-11-27 | Alnylam Pharmaceuticals Inc. | $5,557 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | PFIZER INC. | $1,216 | Travel and Lodging | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2024 | |
| 2024-11-16 | PFIZER INC. | $40 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-28 | Abbott Laboratories | $136 | Food and Beverage | In-kind items and services | CARDIOMEMS Device, Heart Failure | 2024 | |
| 2024-10-22 | AstraZeneca UK Limited | $2,600 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-17 | PFIZER INC. | $3,248 | Consulting Fee | Cash or cash equivalent | VYNDAMAX Drug, CARDIOVASCULAR | 2024 | |
| 2024-10-09 | AstraZeneca Pharmaceuticals LP | $120 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-10-04 | Alnylam Pharmaceuticals Inc. | $2,820 | Consulting Fee | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-10-03 | PFIZER INC. | $2,600 | Honoraria | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2024 | |
| 2024-09-30 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-08-30 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-08-29 | PFIZER INC. | $51 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2024 | |
| 2024-07-17 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | CARDIOMEMS Device, Heart Failure | 2024 | |
| 2024-06-27 | Impulse Dynamics (USA) Inc. | $130 | Food and Beverage | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | 2024 | |
| 2024-05-26 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | VYNDAQEL CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-05-17 | Abbott Laboratories | $1 | Food and Beverage | In-kind items and services | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | 2024 | |
| 2024-05-08 | AstraZeneca Pharmaceuticals LP | $96 | Food and Beverage | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-04-19 | Alnylam Pharmaceuticals Inc. | $2,291 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-04-11 | Paragonix Technologies, Inc. | $142 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-11 | Paragonix Technologies, Inc. | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-11 | Paragonix Technologies, Inc. | $1 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-04 | Alnylam Pharmaceuticals Inc. | $9,366 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-03-11 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | VYNDAQEL CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-02-28 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-01-26 | PFIZER INC. | $780 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-01-24 | AstraZeneca Pharmaceuticals LP | $96 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-18 | Alnylam Pharmaceuticals Inc. | $4,680 | Consulting Fee | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2024 | |
| 2024-01-18 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-01-18 | AstraZeneca Pharmaceuticals LP | $6 | Food and Beverage (3 payments) | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $122 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2024 | |
| 2024-01-11 | Alnylam Pharmaceuticals Inc. | $107 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2024 | |
| 2024-01-10 | Alnylam Pharmaceuticals Inc. | $111 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2024 | |
| 2023-12-15 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2023 |
| 2023-12-12 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2023 |
| 2023-12-07 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2023 |
| 2023-11-21 | AstraZeneca Pharmaceuticals LP | $2,148 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-04 | Alnylam Pharmaceuticals Inc. | $301 | Travel and Lodging | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-11-04 | Alnylam Pharmaceuticals Inc. | $249 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-11-03 | Alnylam Pharmaceuticals Inc. | $239 | Travel and Lodging | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-11-02 | Alnylam Pharmaceuticals Inc. | $370 | Consulting Fee | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-11-02 | Alnylam Pharmaceuticals Inc. | $249 | Travel and Lodging | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $217 | Travel and Lodging | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-11-01 | Abbott Laboratories | $6 | Food and Beverage | In-kind items and services | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | 2023 | |
| 2023-10-31 | Alnylam Pharmaceuticals Inc. | $9,435 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-10-31 | Alnylam Pharmaceuticals Inc. | $264 | Travel and Lodging | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-10-31 | Alnylam Pharmaceuticals Inc. | $245 | Travel and Lodging | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-10-10 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2023 |
| 2023-10-09 | AstraZeneca Pharmaceuticals LP | $119 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-06 | PFIZER INC. | $43 | Food and Beverage | In-kind items and services | VYNDAMAX Drug, CARDIOVASCULAR | 2023 | |
| 2023-09-07 | AstraZeneca Pharmaceuticals LP | $1,611 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-15 | PFIZER INC. | $8,820 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-07 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2023 |
| 2023-07-31 | PFIZER INC. | $5,300 | Honoraria | Cash or cash equivalent | 2023 | ||
| 2023-07-20 | Impulse Dynamics (USA) Inc. | $173 | Food and Beverage | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | 2023 | |
| 2023-06-06 | E.R. Squibb & Sons, L.L.C. | $124 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2023 | |
| 2023-05-11 | PFIZER INC. | $780 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2023 |
| 2023-04-26 | Kestra Medical Technology Services, Inc. | $62 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology | 2023 | |
| 2023-04-01 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2023 |
| 2023-03-27 | Abbott Laboratories | $179 | Food and Beverage | In-kind items and services | MITRACLIP Device, Vascular | 2023 | |
| 2023-03-15 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $95 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2023 | |
| 2023-03-02 | Alnylam Pharmaceuticals Inc. | $5,557 | Consulting Fee | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | 2023 | |
| 2022-12-14 | AstraZeneca Pharmaceuticals LP | $1,611 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-08 | Life Molecular Imaging Ltd | $90 | Food and Beverage | Cash or cash equivalent | NEURACEQ Drug, Diagnostic Tracer | 2022 | |
| 2022-08-19 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | 2022 |
| 2022-08-04 | PFIZER INC. | $3,465 | Honoraria | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2022 | |
| 2022-08-03 | Alexion Pharmaceuticals, Inc. | $2,520 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-20 | Novo Nordisk AS | $3,750 | Consulting Fee | Cash or cash equivalent | Tresiba Drug, Diabetes | 2022 | |
| 2022-06-14 | PFIZER INC. | $780 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2022 |
| 2022-05-11 | Alexion Pharmaceuticals, Inc. | $2,240 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-03 | PFIZER INC. | $780 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2022 |
| 2022-04-21 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2022 |
| 2022-02-07 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2022 |
| 2021-11-15 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2021 |
| 2021-10-11 | PFIZER INC. | $3,500 | Honoraria | Cash or cash equivalent | 2021 | ||
| 2021-10-07 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $100 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2021 | |
| 2021-06-10 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2021 |
| 2020-12-31 | PFIZER INC. | $5,000 | Honoraria | Cash or cash equivalent | 2020 | ||
| 2020-11-09 | Alnylam Pharmaceuticals Inc. | $3,510 | Consulting Fee | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | 2020 | |
| 2020-10-06 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-09-18 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-09-18 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-09-01 | PFIZER INC. | $940 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-08-06 | PFIZER INC. | $13,200 | Honoraria | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2020 | |
| 2020-07-02 | Alnylam Pharmaceuticals Inc. | $4,095 | Consulting Fee | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | 2020 | |
| 2020-06-25 | PFIZER INC. | $1,400 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-06-18 | Akcea Therapeutics, Inc. | $3,175 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-05-16 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-04-20 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-04-07 | PFIZER INC. | $1,400 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2020-02-14 | PFIZER INC. | $330 | Research payment | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | TAFAMIDIS CLINICAL PUBLICATION PROGRAM | 2020 |
| 2019-12-30 | PFIZER INC. | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2019 | |
| 2019-12-03 | PFIZER INC. | $330 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2019 | |
| 2019-11-27 | PFIZER INC. | $330 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2019 | |
| 2019-11-13 | Lilly USA, LLC | $73 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2019 | |
| 2019-11-13 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2019 | |
| 2019-10-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $124 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-10-02 | ABIOMED | $22 | Food and Beverage | In-kind items and services | Impella Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-09-16 | PFIZER INC. | $940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2019 | |
| 2019-09-16 | PFIZER INC. | $940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2019 | |
| 2019-09-13 | Alnylam Pharmaceuticals Inc. | $115 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2019 | |
| 2019-08-26 | PFIZER INC. | $13,200 | Consulting Fee | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2019 | |
| 2019-05-20 | Alnylam Pharmaceuticals Inc. | $100 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2019 | |
| 2019-03-29 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2019 | |
| 2019-01-30 | Alnylam Pharmaceuticals Inc. | $135 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-01-29 | Alnylam Pharmaceuticals Inc. | $377 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-01-29 | Alnylam Pharmaceuticals Inc. | $357 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-01-29 | Alnylam Pharmaceuticals Inc. | $135 | Travel and Lodging | In-kind items and services | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | Eidos Therapeutics, Inc. | Cleveland Clinic Hospital | $2,128 | An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin | 2025 |
| 2025-10-31 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $6,137 | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI | 2025 |
| 2025-10-24 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $4,622 | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT | 2025 |
| 2025-10-03 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $20,282 | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT | 2025 |
| 2025-10-02 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $5,860 | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI | 2025 |
| 2025-09-12 | Eidos Therapeutics, Inc. | Cleveland Clinic Hospital | $1,755 | An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin | 2025 |
| 2025-09-01 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $4,075 | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI | 2025 |
| 2025-08-20 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $4,845 | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT | 2025 |
| 2025-07-28 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $14,627 | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT | 2025 |
| 2025-07-28 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $16,629 | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI | 2025 |
| 2025-07-25 | Alexion Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $384,242 | a phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid dep | 2025 |
| 2025-07-17 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $22,145 | An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis | 2025 |
| 2025-07-01 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $2,336 | An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Cleveland Clinic Hospital | $6,934 | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT | 2025 |
| 2025-05-20 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $585 | An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis | 2025 |
| 2025-05-15 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $11,895 | An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis | 2025 |
| 2023-12-14 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $390 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-11-29 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $24,800 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-10-27 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $84,900 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-10-27 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $17,050 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-09-08 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $3,190 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-08-24 | PFIZER INC. | Cleveland Clinic Hospital | $958 | A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 20 | 2023 |
| 2023-07-26 | American Regent | Cleveland Clinic Hospital | $1,835 | Heart_FID | 2023 |
| 2023-07-03 | American Regent | Cleveland Clinic Hospital | $200 | Heart_FID | 2023 |
| 2023-06-15 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $390 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-06-14 | American Regent | Cleveland Clinic Hospital | $2,662 | Heart_FID | 2023 |
| 2023-04-12 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $58,486 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-03-27 | Alnylam Pharmaceuticals Inc. | Cleveland Clinic Hospital | $23,250 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy | 2023 |
| 2023-03-06 | American Regent | Cleveland Clinic Hospital | $333 | Heart_FID | 2023 |
| 2023-01-19 | American Regent | Cleveland Clinic Hospital | $5,275 | Heart_FID | 2023 |
| 2022-12-05 | American Regent | Cleveland Clinic Hospital | $333 | Heart_FID | 2022 |
| 2022-11-09 | American Regent | Cleveland Clinic Hospital | $1,814 | Heart_FID | 2022 |
| 2022-10-17 | American Regent | Cleveland Clinic Hospital | $800 | Heart_FID | 2022 |
| 2022-09-08 | American Regent | Cleveland Clinic Hospital | $333 | Heart_FID | 2022 |
| 2022-08-03 | American Regent | Cleveland Clinic Hospital | $5,308 | Heart_FID | 2022 |
| 2022-04-20 | American Regent | Cleveland Clinic Hospital | $2,600 | Heart_FID | 2022 |
| 2022-03-23 | PFIZER INC. | Cleveland Clinic Hospital | $2,500 | A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 20 | 2022 |
| 2022-03-07 | American Regent | Cleveland Clinic Hospital | $333 | Heart_FID | 2022 |
| 2022-01-24 | American Regent | Cleveland Clinic Hospital | $1,100 | Heart_FID | 2022 |
| 2021-12-08 | American Regent | Cleveland Clinic Hospital | $2,647 | Heart_FID | 2021 |
| 2021-10-20 | American Regent | Cleveland Clinic Hospital | $5,708 | Heart_FID | 2021 |
| 2021-07-14 | American Regent | Cleveland Clinic Hospital | $3,200 | Heart_FID | 2021 |
| 2021-06-07 | American Regent | Cleveland Clinic Hospital | $433 | Heart_FID | 2021 |
| 2021-06-04 | PFIZER INC. | Cleveland Clinic Hospital | $234 | A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 20 | 2021 |
| 2021-04-22 | PFIZER INC. | Cleveland Clinic Hospital | $234 | A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 20 | 2021 |
| 2021-04-14 | American Regent | Cleveland Clinic Hospital | $2,708 | Heart_FID | 2021 |
| 2021-01-23 | PFIZER INC. | Cleveland Clinic Hospital | $600 | A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 20 | 2021 |
| 2021-01-22 | PFIZER INC. | Cleveland Clinic Hospital | $4,668 | A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 20 | 2021 |
| 2021-01-11 | American Regent | Cleveland Clinic Hospital | $1,533 | Heart_FID | 2021 |
| 2020-12-23 | PFIZER INC. | Cleveland Clinic Hospital | $1,735 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-11-09 | American Regent | CLEVELAND CLINIC FOUNDATION | $2,347 | Heart_FID | 2020 |
| 2020-10-15 | American Regent | CLEVELAND CLINIC FOUNDATION | $7,350 | Heart_FID | 2020 |
| 2020-09-18 | PFIZER INC. | Cleveland Clinic Hospital | $25,872 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-08-10 | American Regent | CLEVELAND CLINIC FOUNDATION | $333 | Heart_FID | 2020 |
| 2020-07-08 | American Regent | CLEVELAND CLINIC FOUNDATION | $1,400 | Heart_FID | 2020 |
| 2020-04-08 | American Regent | CLEVELAND CLINIC FOUNDATION | $14,950 | Heart_FID | 2020 |
| 2020-04-02 | PFIZER INC. | Cleveland Clinic Hospital | $1,500 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-04-02 | PFIZER INC. | Cleveland Clinic Hospital | $5,100 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-04-02 | PFIZER INC. | Cleveland Clinic Hospital | $2,400 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-04-02 | PFIZER INC. | Cleveland Clinic Hospital | $1,200 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-03-17 | PFIZER INC. | Cleveland Clinic Hospital | $234 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-03-09 | American Regent | CLEVELAND CLINIC FOUNDATION | $933 | Heart_FID | 2020 |
| 2020-03-05 | PFIZER INC. | Cleveland Clinic Hospital | $3,500 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-03-02 | PFIZER INC. | Cleveland Clinic Hospital | $66,500 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-02-12 | American Regent | CLEVELAND CLINIC FOUNDATION | $3,909 | Heart_FID | 2020 |
| 2020-02-06 | PFIZER INC. | Cleveland Clinic Hospital | $219,990 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-01-13 | American Regent | CLEVELAND CLINIC FOUNDATION | $7,475 | Heart_FID | 2020 |
| 2019-12-12 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $11,000 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-12-12 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $234 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-10-09 | American Regent | CLEVELAND CLINIC FOUNDATION | $15,600 | Heart_FID | 2019 |
| 2019-09-17 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $116,774 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-09-17 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $26,225 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-09-16 | American Regent | CLEVELAND CLINIC FOUNDATION | $333 | Heart_FID | 2019 |
| 2019-09-10 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $61,958 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-08-01 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $234 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-08-01 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $100 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-07-18 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $200 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-07-08 | American Regent | CLEVELAND CLINIC FOUNDATION | $9,550 | Heart_FID | 2019 |
| 2019-06-04 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $195 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-04-11 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $234 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-04-11 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $1,300 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-04-10 | American Regent | CLEVELAND CLINIC FOUNDATION | $12,200 | Heart_FID | 2019 |
| 2019-04-09 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $1,500 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-04-09 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $234 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-04-09 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $1,500 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-03-13 | American Regent | CLEVELAND CLINIC FOUNDATION | $333 | Heart_FID | 2019 |
| 2019-01-21 | American Regent | CLEVELAND CLINIC FOUNDATION | $5,000 | Heart_FID | 2019 |
| 2019-01-03 | PFIZER INC. | CLEVELAND CLINIC HOSPITAL | $2,821 | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Independence, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Independence, OH | County Cuyahoga County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 7,534 | 1,245,873 | 11,810,293 |
| Population, 2020 census P1 | 7,584 | 1,264,817 | 11,799,448 |
| Median age B01002 | 48.4 | 40.4 | 39.7 |
| Under 18 B01001 | 19.2% | 20.5% | 22.0% |
| 65 and over B01001 | 25.5% | 19.5% | 18.3% |
| Households B11001 | 3,121 | 554,551 | 4,863,191 |
| Foreign born B05002 | 3.1% | 7.7% | 5.2% |
| Median household income B19013 | $115,733 | $64,468 | $71,389 |
| Median family income B19113 | $126,413 | $89,252 | $92,749 |
| Per capita income B19301 | $58,711 | $42,747 | $40,552 |
| Poverty rate B17001 | 2.4% | 16.1% | 13.3% |
| Unemployment rate B23025 | 1.5% | 6.6% | 4.8% |
| Civilian labor force B23025 | 4,068 | 650,577 | 5,994,779 |
| Mean commute (minutes) B08013 | 22.6 | 23.3 | 23.4 |
| Bachelor's degree or higher B15003 | 47.4% | 36.5% | 31.5% |
| Housing units B25001 | 3,217 | 615,331 | 5,292,391 |
| Owner-occupied B25003 | 90.4% | 59.4% | 67.2% |
| Renters B25003 | 9.6% | 40.6% | 32.8% |
| Median home value B25077 | $309,900 | $195,400 | $214,800 |
| Median gross rent B25064 | $1,383 | $1,060 | $1,034 |
| White, not Hispanic B03002 | 92.4% | 56.5% | 75.8% |
| Black B03002 | 1.8% | 28.5% | 12.0% |
| Hispanic or Latino B03002 | 1.3% | 7.0% | 4.8% |
| Asian B03002 | 1.4% | 3.3% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Independence, OH.
Comments